ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $503,948 | -7.8% | 14,136 | +19.4% | 0.00% | 0.0% |
Q2 2023 | $546,364 | +25.0% | 11,844 | +8.7% | 0.00% | 0.0% |
Q1 2023 | $436,970 | -5.5% | 10,897 | +9.2% | 0.00% | 0.0% |
Q4 2022 | $462,327 | +16.7% | 9,979 | +4.4% | 0.00% | 0.0% |
Q3 2022 | $396,000 | -21.6% | 9,554 | +13.0% | 0.00% | -33.3% |
Q2 2022 | $505,000 | -24.9% | 8,457 | -8.5% | 0.00% | 0.0% |
Q1 2022 | $672,000 | -21.9% | 9,247 | -9.6% | 0.00% | -25.0% |
Q4 2021 | $860,000 | +35.2% | 10,231 | +45.0% | 0.00% | +33.3% |
Q3 2021 | $636,000 | -5.2% | 7,056 | +0.2% | 0.00% | -25.0% |
Q2 2021 | $671,000 | -20.3% | 7,042 | -4.8% | 0.00% | -20.0% |
Q1 2021 | $842,000 | -12.6% | 7,395 | +6.3% | 0.01% | -16.7% |
Q4 2020 | $963,000 | +91.5% | 6,955 | +13.6% | 0.01% | +50.0% |
Q3 2020 | $503,000 | +5.0% | 6,123 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $479,000 | +123.8% | 6,123 | +26.8% | 0.00% | +100.0% |
Q1 2020 | $214,000 | +50.7% | 4,827 | +45.2% | 0.00% | +100.0% |
Q4 2019 | $142,000 | 0.0% | 3,325 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $142,000 | -32.7% | 3,325 | 0.0% | 0.00% | -50.0% |
Q2 2019 | $211,000 | -2.3% | 3,325 | +6.8% | 0.00% | 0.0% |
Q1 2019 | $216,000 | +72.8% | 3,113 | +8.4% | 0.00% | +100.0% |
Q4 2018 | $125,000 | -42.9% | 2,871 | 0.0% | 0.00% | -50.0% |
Q3 2018 | $219,000 | +19.0% | 2,871 | +20.2% | 0.00% | 0.0% |
Q2 2018 | $184,000 | +50.8% | 2,388 | 0.0% | 0.00% | +100.0% |
Q1 2018 | $122,000 | +9.9% | 2,388 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $111,000 | +38.8% | 2,388 | +58.4% | 0.00% | 0.0% |
Q3 2017 | $80,000 | -14.9% | 1,508 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $94,000 | -40.9% | 1,508 | -35.8% | 0.00% | -50.0% |
Q1 2017 | $159,000 | -3.6% | 2,348 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $165,000 | +63.4% | 2,348 | +64.7% | 0.00% | +100.0% |
Q3 2016 | $101,000 | +152.5% | 1,426 | +72.6% | 0.00% | 0.0% |
Q2 2016 | $40,000 | -23.1% | 826 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $52,000 | -44.1% | 826 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $93,000 | +322.7% | 826 | +267.1% | 0.00% | – |
Q3 2015 | $22,000 | +120.0% | 225 | +125.0% | 0.00% | – |
Q2 2015 | $10,000 | +66.7% | 100 | 0.0% | 0.00% | – |
Q1 2015 | $6,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |